Specification
| Target | IL-17A |
| Clone | Brodalumab |
| Isotype | Human IgG2-Kappa |
| Expression System | CHO |
| Purification | Protein A |
| Recommended Isotope Control | Anti-HEL Human IgG2-Kappa Isotype control |
| Recommended Dilution Buffer | PBS, pH 7.70 |
| Formulation | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Storage | This antibody can be storaged at 2°C to 8 °C for 2 weeks under sterile conditions;-20°C for 3 months under sterile conditions;-70°C for 36 months under sterile conditions.Avoid repeated freeze-thaw. |
| Disclaim | For Research Use Only |
Background
| Background | Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis. |
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |